Public offering

Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

Retrieved on: 
Thursday, March 7, 2019
Health, Biotechnology, Cardiology, Oncology, Pharmaceutical, Finance, Money, Economy, Corporate finance, Initial public offering, Equity securities, Stock market, Stock, Public offering, Prospectus, Preferred stock, Convertible security

Epizyme, Inc. (Nasdaq:EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock.

Key Points: 
  • Epizyme, Inc. (Nasdaq:EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock.
  • The public offering price of each share of common stock is $11.50 and the public offering price of each share of Series A stock is $115.00.
  • In addition, Epizyme has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock and up to an additional 45,652 shares of Series A stock.
  • The offerings of common stock and Series A stock are being made only by means of written prospectuses and prospectus supplements that form a part of the registration statement.

Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

Retrieved on: 
Wednesday, March 6, 2019
Health, Biotechnology, Genetics, Oncology, Pharmaceutical, Finance, Money, Financial economics, Corporate finance, Equity securities, Initial public offering, Stock market, Prospectus, Stock, Preferred stock, Convertible security, Public offering

Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings.

Key Points: 
  • Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings.
  • Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and preferred stock offered in the offering.
  • All of the shares in the proposed offerings are to be sold by Epizyme.
  • The offerings of common stock and Series A stock will be made only by means of written prospectuses and prospectus supplements that form a part of the registration statement.

IMV Inc. Closes Previously Announced Public Offering

Retrieved on: 
Wednesday, March 6, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Professional services, Banking, Finance, Finance, Money, Economy, Initial public offering, Corporate finance, Underwriting, Actuarial science, Public offering, Wells Fargo, IMV, NASDAQ

IMV Inc. (IMV or theCorporation) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the closing of its previously-announced underwritten public offering (theOffering) of 4,900,000common shares at a price to the public of C$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately C$26.7 million, before deducting the underwriting commissions and estimated Offering expenses.

Key Points: 
  • IMV Inc. (IMV or theCorporation) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the closing of its previously-announced underwritten public offering (theOffering) of 4,900,000common shares at a price to the public of C$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately C$26.7 million, before deducting the underwriting commissions and estimated Offering expenses.
  • In addition, the Corporation has granted the underwriters of the Offering a 30-day option to purchase up to an additional 735,000common shares on the same terms and conditions.
  • Wells Fargo Securities and Raymond James acted as joint book-running managers for the Offering.
  • In the press release, such forward-looking statements include, but are not limited to, statements regarding the anticipated use of proceeds from the Offering.

IQVIA Announces Pricing of Secondary Public Offering

Retrieved on: 
Wednesday, March 6, 2019
Technology, Data management, Software, Health, Biotechnology, Pharmaceutical, Finance, Economy, Money, Initial public offering, Corporate finance, Financial markets, IQVIA, Stock market, Prospectus, Public offering, Stock, TPG Capital

IQVIA Holdings Inc. (IQVIA) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the Selling Stockholders), at a price to the public of $141.00 per share.

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the Selling Stockholders), at a price to the public of $141.00 per share.
  • IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering.
  • IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility.
  • Before you invest, you should read the registration statement, the prospectus, the accompanying prospectus supplement and other documents IQVIA has made available with the SEC for information about IQVIA and the offering.

IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock

Retrieved on: 
Tuesday, March 5, 2019
Technology, Data management, Software, Health, Biotechnology, Pharmaceutical, General Health, Finance, Economy, Money, Corporate finance, Stock market, Financial markets, IQVIA, Initial public offering, Stock, Repurchase agreement, Public offering

IQVIA Holdings Inc. (IQVIA) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the Selling Stockholders), of which IQVIA intends to repurchase from the underwriter 1,000,000 shares (the Repurchase).

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the Selling Stockholders), of which IQVIA intends to repurchase from the underwriter 1,000,000 shares (the Repurchase).
  • IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering.
  • IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility.
  • The Repurchase is subject to completion of the offering and the satisfaction of other customary conditions.

Preferred Apartment Communities, Inc. Recognized as one of Atlanta's Best Places to Work in 2019

Retrieved on: 
Wednesday, March 6, 2019
Initial public offering, Financial markets, Workplace, Prospectus, Public offering

"We are extremely proud of our many associates and very much appreciate their commitment back to the Company.

Key Points: 
  • "We are extremely proud of our many associates and very much appreciate their commitment back to the Company.
  • The survey measures several aspects of workplace culture, such as overall happiness, management performance, workplace environment and career progression opportunities.
  • At December 31, 2018, the Company was the approximate 97.9% owner of Preferred Apartment Communities Operating Partnership, L.P., the Company's operating partnership.
  • The mShares Redeemable Preferred Stock Offering prospectus, dated January 19, 2017, can be accessed through the following link:

Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027

Retrieved on: 
Tuesday, March 5, 2019
Finance, Economy, Money, Financial markets, Initial public offering, Corporate finance, Stock market, Public offering, Security, NASDAQ, Shelf registration

MADISON, Wis., March 5, 2019 /PRNewswire/ --Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3.

Key Points: 
  • MADISON, Wis., March 5, 2019 /PRNewswire/ --Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3.
  • The Company has also granted the underwriter a 30-day option to purchase up to an additional $90.0 million aggregate principal amount of the Notes.
  • The cash portion of such consideration will be funded from a portion of the net proceeds from this offering.
  • The Company may also exchange or induce conversions of the 2025 Notes following completion of this offering and may fund such exchanges or conversions with the proceeds of this offering.

Digital Realty Announces Pricing of Preferred Stock Offering

Retrieved on: 
Monday, March 4, 2019
Finance, Money, Economy, Stock market, Corporate finance, Financial markets, Equity securities, Preferred stock, Security, Shelf registration, Public offering, Merrill Lynch

SAN FRANCISCO, March 4, 2019 /PRNewswire/ --Digital Realty (NYSE: DLR), a leading global provider of data center, colocation and interconnection solutions, announced today the pricing of an underwritten public offering of 8,000,000 shares of 5.850% Series K Cumulative Redeemable Preferred Stock with a liquidation preference of $25.00 per share for gross proceeds of $200 million.

Key Points: 
  • SAN FRANCISCO, March 4, 2019 /PRNewswire/ --Digital Realty (NYSE: DLR), a leading global provider of data center, colocation and interconnection solutions, announced today the pricing of an underwritten public offering of 8,000,000 shares of 5.850% Series K Cumulative Redeemable Preferred Stock with a liquidation preference of $25.00 per share for gross proceeds of $200 million.
  • The preferred stock offering is expected to close on March 13, 2019, subject to customary closing conditions.
  • Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are the joint book-running managers for the preferred stock offering.
  • The preferred stock offering was made under an effective shelf registration statement filed with the Securities and Exchange Commission.

Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering

Retrieved on: 
Friday, March 1, 2019
Finance, Money, Financial economics, Corporate finance, Initial public offering, Stock market, Equity securities, Financial markets, Stock, Preferred stock, Public offering, Prospectus

The amounts sold include 1,100,000 shares of common stock and150,000 shares of Mandatory Convertible Preferred Stock issued pursuant to the exercise in full of the separate options granted to the underwriters in each of the respective offerings to purchase additional shares.

Key Points: 
  • The amounts sold include 1,100,000 shares of common stock and150,000 shares of Mandatory Convertible Preferred Stock issued pursuant to the exercise in full of the separate options granted to the underwriters in each of the respective offerings to purchase additional shares.
  • The net proceeds from the common stock offering and the Mandatory Convertible Preferred Stock offering were approximately $1.44 billion and $1.60 billion, respectively (which includes the proceeds of the exercise in full of the underwriters' options to purchase additional shares in the respective offerings), in each case after deducting issuance costs and discounts.
  • If for any reason the acquisition is not completed, Danaher expects to use the net proceeds from the offerings for general corporate purposes.
  • Each offering was made only by means of a prospectus supplement relating to such offering and the accompanying base prospectus.

Sage Therapeutics Prices Public Offering of Common Stock

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Finance, Money, Economy, Initial public offering, Stock market, Corporate finance, Goldman Sachs, Subprime mortgage crisis, Security, Public offering

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $150.00 per share.

Key Points: 
  • Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $150.00 per share.
  • The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $500 million.
  • In addition, Sage has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of its common stock.
  • Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering.